104 results
Page 4 of 6
8-K
EX-99.3
lhla95ha1wom
4 Sep 12
Other Events
12:00am
8-K
EX-99.1
qnrwpqrugyp5e7g0q
22 May 12
Other Events
12:00am
8-K
EX-99.3
r04v vzvounvpdleb5k3
22 May 12
Other Events
12:00am
8-K
EX-99.4
wbrcus9
22 May 12
Other Events
12:00am
8-K
EX-99.2
preww7zhonb8lj6wu6f
22 May 12
Other Events
12:00am
8-K
fbrn6u1z7
22 May 12
Other Events
12:00am
8-K
EX-99
x18lw3 5gj
26 Apr 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99
iwcnf
27 Oct 11
Results of Operations and Financial Condition
12:00am
8-K
EX-99.2
r44eh7 959jttd5r7vc
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
fgmvaygj
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.3
8cagxxyqzllc0c41v9
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.4
0v8c xhdid1sed
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.1
8vf42yy
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99
jvj vvvpk
28 Jul 11
Results of Operations and Financial Condition
12:00am
8-K
n7g1a klm0t12sbfe
17 May 11
Dose-related efficacy and optimal once-daily dosing interval of the long-acting beta2
12:00am
8-K
EX-99.1
edjhxyy6paiw
17 May 11
Dose-related efficacy and optimal once-daily dosing interval of the long-acting beta2
12:00am
8-K
EX-99
uqxwaz8 vlwjmpozd
21 Oct 10
Results of Operations and Financial Condition
12:00am
8-K
bn5966
22 Sep 10
Other Events
12:00am
8-K
EX-99
0hw4wt
22 Sep 10
Other Events
12:00am